Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections.

MedStar author(s):
Citation: Expert Review of Antiinfective Therapy. 15(10):935-945, 2017 Oct.PMID: 28901793Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Anti-Bacterial Agents/ad [Administration & Dosage] | *Anti-Bacterial Agents/tu [Therapeutic Use] | *Bacterial Infections/dt [Drug Therapy] | *Fosfomycin/ad [Administration & Dosage] | *Fosfomycin/tu [Therapeutic Use] | Administration, Intravenous | Anti-Bacterial Agents/ae [Adverse Effects] | Anti-Bacterial Agents/pd [Pharmacology] | Bacterial Infections/mi [Microbiology] | Drug Resistance, Bacterial | Fosfomycin/ae [Adverse Effects] | Fosfomycin/pd [Pharmacology] | Hospitalization | Humans | InpatientsYear: 2017ISSN:
  • 1478-7210
Name of journal: Expert review of anti-infective therapyAbstract: INTRODUCTION: With the worldwide increase in the rates of antimicrobial resistance, antimicrobials with novel mechanisms of action are needed to fill a void in the antimicrobial armamentarium. Areas Covered: Intravenous fosfomycin has been studied extensively in a wide variety of infections including cUTI, lower respiratory tract infection, bone and joint infections, endocarditis, meningitis, and bacteremia outside of the United States. This paper reviews the in vitro activity, pharmacokinetic properties, and clinical experience of intravenous fosfomycin in hospitalized patients with serious infections. Expert Commentary: Drug resistant infections in hospitalized and critically ill patients are associated with high morbidity and mortality. Fosfomycin is an epoxide antimicrobial that acts by inhibiting cell wall synthesis earlier in the process compared to other classes of antimicrobial agents. Fosfomycin exerts bactericidal activity against a broad range of gram-negative and gram-positive pathogens, including extended-spectrum beta-lactamase- and carbapenemase-producing bacteria. Although an oral formulation of fosfomycin is approved by the United States (US) Food and Drug Administration for uncomplicated urinary tract infections, intravenous fosfomycin at a dose of 18 gm/day is currently under clinical development for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis in the US.All authors: Mohr JF, Pogue JM, Shorr AFFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2017-09-18
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28901793 Available 28901793

INTRODUCTION: With the worldwide increase in the rates of antimicrobial resistance, antimicrobials with novel mechanisms of action are needed to fill a void in the antimicrobial armamentarium. Areas Covered: Intravenous fosfomycin has been studied extensively in a wide variety of infections including cUTI, lower respiratory tract infection, bone and joint infections, endocarditis, meningitis, and bacteremia outside of the United States. This paper reviews the in vitro activity, pharmacokinetic properties, and clinical experience of intravenous fosfomycin in hospitalized patients with serious infections. Expert Commentary: Drug resistant infections in hospitalized and critically ill patients are associated with high morbidity and mortality. Fosfomycin is an epoxide antimicrobial that acts by inhibiting cell wall synthesis earlier in the process compared to other classes of antimicrobial agents. Fosfomycin exerts bactericidal activity against a broad range of gram-negative and gram-positive pathogens, including extended-spectrum beta-lactamase- and carbapenemase-producing bacteria. Although an oral formulation of fosfomycin is approved by the United States (US) Food and Drug Administration for uncomplicated urinary tract infections, intravenous fosfomycin at a dose of 18 gm/day is currently under clinical development for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis in the US.

English

Powered by Koha